PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 28830790-2 2017 The potent anticancer agent topotecan is a substrate of efflux transporters BCRP and P-gp, which are expressed at the BRB to restrict vitreous and retinal distribution of xenobiotics. Topotecan 28-37 ATP binding cassette subfamily G member 2 (Junior blood group) Mus musculus 76-80 14566825-2 2003 Expression of wild-type BCRP confers resistance to multiple chemotherapeutic agents such as mitoxantrone, SN-38 and topotecan, but not to doxorubicin. Topotecan 116-125 ATP binding cassette subfamily G member 2 (Junior blood group) Mus musculus 24-28 12089223-1 2002 PURPOSE: We discovered that breast cancer resistance protein (BCRP), a recently identified adenosine triphosphate-binding cassette drug transporter, substantially limits the oral bioavailability of topotecan in mdr1a/1b(-/-) P-glycoprotein (P-gp) knockout and wild-type mice. Topotecan 198-207 ATP binding cassette subfamily G member 2 (Junior blood group) Mus musculus 62-66 10485464-0 1999 The mouse Bcrp1/Mxr/Abcp gene: amplification and overexpression in cell lines selected for resistance to topotecan, mitoxantrone, or doxorubicin. Topotecan 105-114 ATP binding cassette subfamily G member 2 (Junior blood group) Mus musculus 10-15 10485464-0 1999 The mouse Bcrp1/Mxr/Abcp gene: amplification and overexpression in cell lines selected for resistance to topotecan, mitoxantrone, or doxorubicin. Topotecan 105-114 ATP binding cassette subfamily G member 2 (Junior blood group) Mus musculus 20-24 10485464-6 1999 Our data argue strongly that mouse Bcrp1 is functionally comparable with human BCRP, conferring multidrug resistance to topotecan, mitoxantrone, doxorubicin, and related compounds. Topotecan 120-129 ATP binding cassette subfamily G member 2 (Junior blood group) Mus musculus 35-40 15685169-2 2005 Here we show that the multidrug transporter BCRP (encoded by ABCG2) is strongly induced in the mammary gland of mice, cows and humans during lactation and that it is responsible for the active secretion of clinically and toxicologically important substrates such as the dietary carcinogen PhIP, the anticancer drug topotecan and the antiulcerative cimetidine into mouse milk. Topotecan 315-324 ATP binding cassette subfamily G member 2 (Junior blood group) Mus musculus 61-66 12089223-1 2002 PURPOSE: We discovered that breast cancer resistance protein (BCRP), a recently identified adenosine triphosphate-binding cassette drug transporter, substantially limits the oral bioavailability of topotecan in mdr1a/1b(-/-) P-glycoprotein (P-gp) knockout and wild-type mice. Topotecan 198-207 ATP binding cassette subfamily G member 2 (Junior blood group) Mus musculus 28-60 11956086-3 2002 Although the mouse Bcrp1 amino acid substitutions (M or S) are distinct from those seen in the human cell lines (G or T), they all have similar consequences: (a) greater resistance to anthracyclines (and bisantrene); (b) relatively lower resistance to topotecan; (c) greatly enhanced efflux of the dye rhodamine 123. Topotecan 252-261 ATP binding cassette subfamily G member 2 (Junior blood group) Mus musculus 19-24 11036110-2 2000 BCRP can render tumor cells resistant to the anticancer drugs topotecan, mitoxantrone, doxorubicin, and daunorubicin. Topotecan 62-71 ATP binding cassette subfamily G member 2 (Junior blood group) Mus musculus 0-4 11036110-5 2000 Bcrp1, the murine homologue of BCRP, was expressed in the polarized mammalian cell lines LLC-PK1 and MDCK-II, and the direction of Bcrp1-mediated transport of topotecan and mitoxantrone was determined. Topotecan 159-168 ATP binding cassette subfamily G member 2 (Junior blood group) Mus musculus 0-5 11036110-5 2000 Bcrp1, the murine homologue of BCRP, was expressed in the polarized mammalian cell lines LLC-PK1 and MDCK-II, and the direction of Bcrp1-mediated transport of topotecan and mitoxantrone was determined. Topotecan 159-168 ATP binding cassette subfamily G member 2 (Junior blood group) Mus musculus 31-35 11036110-6 2000 To avoid the confounding drug transport provided by P-glycoprotein (P-gp), the roles of Bcrp1 in the bioavailability of topotecan and the effect of GF120918 were studied in both wild-type and P-gp-deficient mice and their fetuses. Topotecan 120-129 ATP binding cassette subfamily G member 2 (Junior blood group) Mus musculus 88-93 11036110-10 2000 In pregnant GF120918-treated, P-gp-deficient mice, relative fetal penetration of topotecan was twofold higher than that in pregnant vehicle-treated mice, suggesting a function for BCRP in the maternal-fetal barrier of the placenta. Topotecan 81-90 ATP binding cassette subfamily G member 2 (Junior blood group) Mus musculus 180-184 11036110-12 2000 We propose that strategic application of BCRP inhibitors may thus lead to more effective oral chemotherapy with topotecan or other BCRP substrate drugs. Topotecan 112-121 ATP binding cassette subfamily G member 2 (Junior blood group) Mus musculus 41-45 33804018-7 2021 Moreover, the absorption rate of topotecan, a BCRP substrate, in wild-type mice pretreated with LY335979 was similar to that in mdr1a/1b knockout mice but significantly lower than that in bcrp knockout mice. Topotecan 33-42 ATP binding cassette subfamily G member 2 (Junior blood group) Mus musculus 46-50 33804018-7 2021 Moreover, the absorption rate of topotecan, a BCRP substrate, in wild-type mice pretreated with LY335979 was similar to that in mdr1a/1b knockout mice but significantly lower than that in bcrp knockout mice. Topotecan 33-42 ATP binding cassette subfamily G member 2 (Junior blood group) Mus musculus 188-192 29212189-6 2017 Importantly, quizartinib at 30 mg/kg strongly enhanced the effect of topotecan (3 mg/kg) in ABCG2-overexpressing (H460/MX20) xenografts in athymic nude mice. Topotecan 69-78 ATP binding cassette subfamily G member 2 (Junior blood group) Mus musculus 92-97 28830790-3 2017 In this work we have studied vitreous and retinal distribution, tumor accumulation and antitumor activity of topotecan, using pantoprazole as inhibitor of BCRP and P-gp. Topotecan 109-118 ATP binding cassette subfamily G member 2 (Junior blood group) Mus musculus 155-159 26515463-10 2015 In a murine model system, combination treatment of A-803467 (35 mg/kg) and topotecan (3 mg/kg) significantly inhibited the tumor growth in mice xenografted with ABCG2-overexpressing cancer cells. Topotecan 75-84 ATP binding cassette subfamily G member 2 (Junior blood group) Mus musculus 161-166 26515463-2 2015 The diverse range of substrates of ABCG2 includes many antineoplastic agents such as topotecan, doxorubicin and mitoxantrone. Topotecan 85-94 ATP binding cassette subfamily G member 2 (Junior blood group) Mus musculus 35-40 26199091-4 2015 By screening ABC substrates against mouse G3 medulloblastoma tumorspheres in vitro, we found that Abcg2 inhibition could potentiate responses to the clinically used drug topotecan, producing a more than 9-fold suppression of cell proliferation. Topotecan 170-179 ATP binding cassette subfamily G member 2 (Junior blood group) Mus musculus 98-103 26199091-5 2015 Extended studies in vivo in this model confirmed that Abcg2 inhibition was sufficient to enhance antiproliferative responses to topotecan, producing a significant survival advantage compared with subjects treated with topotecan alone. Topotecan 128-137 ATP binding cassette subfamily G member 2 (Junior blood group) Mus musculus 54-59 26199091-5 2015 Extended studies in vivo in this model confirmed that Abcg2 inhibition was sufficient to enhance antiproliferative responses to topotecan, producing a significant survival advantage compared with subjects treated with topotecan alone. Topotecan 218-227 ATP binding cassette subfamily G member 2 (Junior blood group) Mus musculus 54-59 23635651-8 2013 It is concluded that Abcg2 has the most significant effect on topotecan elimination, whereas both Abcb1 and Abcc2 have overlapping functions with Abcg2. Topotecan 62-71 ATP binding cassette subfamily G member 2 (Junior blood group) Mus musculus 21-26 23028879-0 2012 EZN-2208 (PEG-SN38) overcomes ABCG2-mediated topotecan resistance in BRCA1-deficient mouse mammary tumors. Topotecan 45-54 ATP binding cassette subfamily G member 2 (Junior blood group) Mus musculus 30-35 23028879-5 2012 We also evaluated tumor-specific ABCG2 inhibition by Ko143 in Abcg2(-/-) host animals that carried tumors with topotecan-induced ABCG2 expression. Topotecan 111-120 ATP binding cassette subfamily G member 2 (Junior blood group) Mus musculus 129-134 21718946-0 2011 Evaluation of the P-glycoprotein- and breast cancer resistance protein-mediated brain penetration of 11C-labeled topotecan using small-animal positron emission tomography. Topotecan 113-122 ATP binding cassette subfamily G member 2 (Junior blood group) Mus musculus 38-70 20145144-8 2010 Tumor-specific genetic ablation of Abcg2 significantly increased overall survival of topotecan-treated animals (P < 0.001), confirming the in vivo relevance of ABCG2 for topotecan resistance in a novel approach. Topotecan 85-94 ATP binding cassette subfamily G member 2 (Junior blood group) Mus musculus 35-40 21309545-1 2011 P-glycoprotein (P-gp/ABCB1) and breast cancer resistance protein (BCRP/ABCG2) combination knockout mice display disproportionately increased brain penetration of shared substrates, including topotecan and several tyrosine kinase inhibitors, compared to mice deficient for only one transporter. Topotecan 191-200 ATP binding cassette subfamily G member 2 (Junior blood group) Mus musculus 66-70 21309545-5 2011 ABCB1 and ABCG2 contributed to similar extents to topotecan transport, which was only partly saturable. Topotecan 50-59 ATP binding cassette subfamily G member 2 (Junior blood group) Mus musculus 10-15 20145144-8 2010 Tumor-specific genetic ablation of Abcg2 significantly increased overall survival of topotecan-treated animals (P < 0.001), confirming the in vivo relevance of ABCG2 for topotecan resistance in a novel approach. Topotecan 173-182 ATP binding cassette subfamily G member 2 (Junior blood group) Mus musculus 35-40 19567673-1 2009 Topotecan is a substrate of the ATP-binding cassette transporters P-glycoprotein (P-gp/MDR1) and breast cancer resistance protein (BCRP). Topotecan 0-9 ATP binding cassette subfamily G member 2 (Junior blood group) Mus musculus 97-129 19802874-0 2009 ABCG2-associated resistance to Hoechst 33342 and topotecan in a murine cell model with constitutive expression of side population characteristics. Topotecan 49-58 ATP binding cassette subfamily G member 2 (Junior blood group) Mus musculus 0-5 19802874-7 2009 Hoechst 33342-resistant murine cells showed lower but significant crossresistance to topotecan, again attributable to enhanced ABCG2 expression, enabling cells to evade S-phase arrest. Topotecan 85-94 ATP binding cassette subfamily G member 2 (Junior blood group) Mus musculus 127-132 19567673-1 2009 Topotecan is a substrate of the ATP-binding cassette transporters P-glycoprotein (P-gp/MDR1) and breast cancer resistance protein (BCRP). Topotecan 0-9 ATP binding cassette subfamily G member 2 (Junior blood group) Mus musculus 131-135 19567673-8 2009 Preferential active transport of topotecan lactone over topotecan carboxylate was shown in vivo by vCSF lactone-to-carboxylate area under the curve ratios for wild-type, Mdr1a/b(-/-), Bcrp1(-/-), and Mdr1a/b(-/-)Bcrp1(-/-) mice of 5.69 +/- 0.83, 3.85 +/- 0.64, 3.61 +/- 0.46, and 0.78 +/- 0.19, respectively. Topotecan 33-50 ATP binding cassette subfamily G member 2 (Junior blood group) Mus musculus 184-189 19567673-8 2009 Preferential active transport of topotecan lactone over topotecan carboxylate was shown in vivo by vCSF lactone-to-carboxylate area under the curve ratios for wild-type, Mdr1a/b(-/-), Bcrp1(-/-), and Mdr1a/b(-/-)Bcrp1(-/-) mice of 5.69 +/- 0.83, 3.85 +/- 0.64, 3.61 +/- 0.46, and 0.78 +/- 0.19, respectively. Topotecan 33-50 ATP binding cassette subfamily G member 2 (Junior blood group) Mus musculus 212-217 19567673-9 2009 Our results suggest that Bcrp1 and P-gp transport topotecan into vCSF and out of brain parenchyma through the blood-brain barrier. Topotecan 50-59 ATP binding cassette subfamily G member 2 (Junior blood group) Mus musculus 25-30 17975156-0 2007 P-glycoprotein and breast cancer resistance protein: two dominant transporters working together in limiting the brain penetration of topotecan. Topotecan 133-142 ATP binding cassette subfamily G member 2 (Junior blood group) Mus musculus 19-51 18523872-5 2008 RESULTS: The Bcrp inhibitor Ko143 blocked topotecan and ABZSO transport in a concentration-dependent manner. Topotecan 42-51 ATP binding cassette subfamily G member 2 (Junior blood group) Mus musculus 13-17 19047120-1 2008 PURPOSE: Topotecan resistance can result from drug efflux by P-glycoprotein (Pgp) and breast cancer resistance protein (BCRP) as well as survival signals initiated by epidermal growth factor receptor family members. Topotecan 9-18 ATP binding cassette subfamily G member 2 (Junior blood group) Mus musculus 86-118 19047120-1 2008 PURPOSE: Topotecan resistance can result from drug efflux by P-glycoprotein (Pgp) and breast cancer resistance protein (BCRP) as well as survival signals initiated by epidermal growth factor receptor family members. Topotecan 9-18 ATP binding cassette subfamily G member 2 (Junior blood group) Mus musculus 120-124 19047120-6 2008 RESULTS: Lapatinib increased topotecan accumulation in BCRP- or Pgp-expressing cells in vitro, and the combination showed enhanced efficacy in HER2+ BT474 xenografts. Topotecan 29-38 ATP binding cassette subfamily G member 2 (Junior blood group) Mus musculus 55-59 17975156-5 2007 RESULTS: The area under the plasma and tissue concentration-time curve (AUC) of topotecan in brains of Mdr1a/b(-/-) and Bcrp1(-/-) mice was only 1.5-fold higher compared with WT mice, but in Mdr1a/b(-/-)Bcrp1(-/-) mice, where both transporters are absent, the AUC increased by 12-fold. Topotecan 80-89 ATP binding cassette subfamily G member 2 (Junior blood group) Mus musculus 120-125 17975156-5 2007 RESULTS: The area under the plasma and tissue concentration-time curve (AUC) of topotecan in brains of Mdr1a/b(-/-) and Bcrp1(-/-) mice was only 1.5-fold higher compared with WT mice, but in Mdr1a/b(-/-)Bcrp1(-/-) mice, where both transporters are absent, the AUC increased by 12-fold. Topotecan 80-89 ATP binding cassette subfamily G member 2 (Junior blood group) Mus musculus 203-208 17975156-8 2007 The P-gp/BCRP inhibitor elacridar fully inhibited P-gp-mediated transport of topotecan, whereas inhibition of Bcrp1-mediated transport by elacridar was minimal. Topotecan 77-86 ATP binding cassette subfamily G member 2 (Junior blood group) Mus musculus 9-13 17975156-9 2007 CONCLUSIONS: Our results using Mdr1a/b(-/-)Bcrp1(-/-) mice clearly show the effect of Bcrp1 at the BBB and also show how two drug transporters act in concert to limit the brain penetration of topotecan. Topotecan 192-201 ATP binding cassette subfamily G member 2 (Junior blood group) Mus musculus 86-91 17145877-10 2006 These results are consistent with the possibility that expression of Bcrp1 and P-glycoprotein at the apical side of the choroid plexus facilitates an influx transport mechanism across the blood-cerebrospinal fluid barrier, resulting in high topotecan CSF penetration. Topotecan 241-250 ATP binding cassette subfamily G member 2 (Junior blood group) Mus musculus 69-74 16651435-5 2006 In our studies, pretreatment of Abcg2(-/-) and Mdr1(a/b)(-/-) mice with gefitinib increased oral absorption and decreased systemic clearance of topotecan, a model substrate, indicating that additional transporters were inhibited. Topotecan 144-153 ATP binding cassette subfamily G member 2 (Junior blood group) Mus musculus 32-37